Skip directly to local search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home
workers, building, architect

Manufacturing

NORA Manufacturing Sector Strategic Goals

927ZHNC - 1-Bromopropane Quantitative Risk Assessment

Start Date: 10/1/2008
End Date: 9/30/2010

Principal Investigator (PI)
Name: David Dankovic
Phone: 513-533-8329
E-mail: dad4@cdc.gov
Organization: NIOSH
Sub-Unit: EID
Funded By: NIOSH

Primary Goal Addressed
9.0

Secondary Goal Addressed

None



Attributed to Manufacturing

50%


Project Description

Short Summary

The primary objective of this project is to conduct a quantitative risk assessment for 1 bromopropane, which will contribute to the on-going process of developing a recommended exposure level for this substance. This project will review the available health effects studies for 1 bromopropane in humans and animals and develop recommendations for occupational exposures to 1 bromopropane. This project will contribute to the development of a Current Intelligence Bulletin (CIB), which will summarize the state of the science on adverse health effects and risks to employers and workers who use 1 bromopropane.



Description

The primary objective of this project is to conduct a quantitative risk assessment for 1 bromopropane, which will contribute to the on-going process of developing a recommended exposure level for this substance. This project will review the available health effects studies for 1 bromopropane in humans and animals and identify those studies with dose-response information sufficient for quantitative analysis. It is anticipated that these will be primarily toxicological studies, but human data will be used where possible.



A dose-response analysis will be conducted using benchmark dose methods, for non-cancer endpoints. Toxicological endpoints such as neurotoxicity, reproductive toxicity, and others will be modeled, and both central and lower-bound benchmark dose estimates will be developed. Model averaging techniques will be used where applicable, in situations where multiple models provide statistically adequate fits to the same data set and no single model can be established as clearly preferable. The toxicological endpoints will be assessed for occupational relevance by comparison to the available human health effects data, and one or more benchmark doses will be chosen for extrapolation to humans based on both overall health protectiveness and relevance to human disease. Finally, uncertainty factors will be developed and applied to the benchmark dose estimates, resulting in a range of acceptable 1 bromopropane exposure concentrations for occupational exposures. This information will be communicated to the EID Document Development Branch in the form of a written report suitable for inclusion in a NIOSH Current Intelligence Bulletin. It is anticipated that the final quantitative risk estimates for 1 bromopropane will contribute to the development of a NIOSH Recommended Exposure Level for this substance.



Objectives

The primary objective of this project is to conduct a quantitative risk assessment for 1 bromopropane, which will contribute to the on-going process of developing a recommended exposure level for this substance. This information will be disseminated in the form of a NIOSH Current Intelligence Bulletin, which will summarize health effects studies in humans and animals and provide a quantitative risk assessment of 1 bromopropane.



Mission Relevance

This project fulfills one of NIOSH's primary missions – the development of recommendations and the dissemination of this information on occupational hazards. This project will contribute to the development of a Current Intelligence Bulletin (CIB), which will summarize the state of the science on adverse health effects and risks to employers and workers who use 1 bromopropane.



This project contributes to the following sectors:

Manufacturing (50%)

Goal 9. Enhance the state of knowledge related to emerging risks to occupational safety and health in manufacturing.

Services (50%)

No goal.



This project also contributes to the Cross-Sector Programs:

Authoritative Recommendations Program (50%)

Goal 1. Reduce and prevent occupational injuries, illnesses and fatalities by supporting NORA sector and cross-sector programs – specifically, this project will contribute to this goal by providing quantitative risk assessment supporting development of NIOSH authoritative recommendations documents.



Cancer, Reproductive and Cardiovascular Diseases (50%)

Strategic Goal 3 (09PPCRCSG3): Reduce the incidence of work-related adverse reproductive outcomes. This project specifically supports Activity/Output Goal 3.1.2. (09PPCRCAOG3.1.2); Conduct studies of high-priority exposures to identify and quantify risk of adverse reproductive health associated with workplace exposures. Strategic Goal 5 (09PPCRCSG5) Reduce the incidence and mortality of other chronic diseases, including (but not limited to), work-related neurologic (cerebrovascular) and renal disease.



 
Contact Us:
USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Road Atlanta, GA 30329-4027, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO